Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.40 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11742464 | 0.79 | MAOB (0.40) | MAOBDRD2LTA4HPPARD | |
| SCHEMBL12083017 | 0.70 | PPARD (0.47) | MAOBDRD2LTA4HALDH1A1PPARD | |
| SCHEMBL6215903 | 0.68 | KMT2A (0.50) | ALDH1A1 | |
| SCHEMBL1245425 | 0.68 | SMN1; SMN2 (0.45) | MAOBALDH1A1AOC3 | |
| SCHEMBL10097103 | 0.68 | DRD2 (0.40) | MAOBDRD2LTA4HALDH1A1PPARD | |
| SCHEMBL10096892 | 0.68 | DRD2 (0.40) | MAOBDRD2LTA4HALDH1A1PPARD | |
| SCHEMBL8237725 | 0.67 | NQO1 (0.64) | MAOBLTA4HALDH1A1AOC3 | |
| SCHEMBL30947369 | 0.67 | KCNH2 (0.48) | MAOBALDH1A1AOC3 | |
| SCHEMBL10097037 | 0.67 | DRD2 (0.39) | MAOBDRD2LTA4HALDH1A1PPARD | |
| SCHEMBL6441253 | 0.65 | MAOB (0.41) | MAOBDRD2LTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611091-B1 | Substituted phenylalkanoic acid derivatives and their use for respiratory disease treatment | ASTRAZENECA AB (SE) | 2014-10-29 | — | — | EP | disclosed |
| US-8158820-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-20110166117-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| EP-1799658-A2 | MODULATORS OF CRTH2 REZEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| US-20060264435-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
| WO-2006037982-A2 | MODULATORS OF CRTH2 RECEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | PTGDR2, PTGDR, PTGER2 | MAOB 1790/4885DRD2 661/4885LTA4H 21/4885 |
| US-20110166117-A1 | Novel Compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | MAOB 311/4885DRD2 1530/4885LTA4H 470/4885 |
| US-20060264435-A1 | Novel compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | MAOB 311/4885DRD2 1530/4885LTA4H 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.